Menopause Without HRT: Non-Hormonal Options, Risks, and What the Evidence Actually Shows

Choosing menopause care without systemic hormones

Some people prefer to avoid menopausal hormone therapy. Others have a medical history that makes systemic estrogen inappropriate or requires specialist discussion. The decision can also change over time as symptoms, age, risk factors, and preferences change.

“HRT” can mean different things. Systemic estrogen treats hot flashes throughout the body. If a person has a uterus, systemic estrogen usually requires adequate endometrial protection with a progestogen. Low-dose vaginal estrogen is primarily a local treatment for genitourinary symptoms and generally produces much lower systemic exposure. Contraceptive hormones use different doses and have different goals. These should not be treated as interchangeable categories.

The Menopause Society’s 2023 nonhormone statement recommends cognitive behavioral therapy, clinical hypnosis, certain SSRIs and SNRIs, gabapentin, and fezolinetant based on the evidence available at that time; oxybutynin, weight loss for appropriate patients, and stellate ganglion block had more limited support [1]. Elinzanetant was approved later, in October 2025.

Start by matching treatment to the symptom

Hot flashes, vaginal dryness, insomnia, depression, joint pain, migraine, and sexual pain can occur in the same life stage but do not share one treatment. A useful symptom inventory records:

• hot-flash and night-sweat frequency, severity, and triggers;
• whether awakenings are caused by sweats, insomnia, apnea, pain, urinary symptoms, or mood;
• bleeding pattern and time since the last natural period;
• vaginal dryness, pain with penetration, urinary urgency, or recurrent urinary infections;
• mood symptoms, panic, migraine, medication changes, alcohol, and sleep-disordered breathing;
• cardiovascular, blood-clot, breast, uterine, liver, bone, and pregnancy history.

Unexpected bleeding needs evaluation rather than attribution to menopause. New chest pain, one-sided weakness, severe shortness of breath, or a painful swollen leg requires urgent assessment regardless of treatment choice.

Nonhormonal prescription options for hot flashes

Fezolinetant

Fezolinetant blocks the neurokinin-3 receptor involved in hypothalamic temperature regulation. In the SKYLIGHT 1 randomized phase 3 trial, both studied doses reduced moderate-to-severe vasomotor-symptom frequency and severity more than placebo at weeks 4 and 12; benefit appeared early and persisted during the extension [3]. The U.S. approved dose is determined by the current product label, not by choosing between trial arms.

Safety guidance changed after approval. In September 2024, the FDA warned about rare but serious liver injury after a postmarketing case and strengthened testing and symptom instructions [4]. Current prescribing requires baseline liver evaluation and scheduled monitoring. Fatigue, nausea, itching, jaundice, dark urine, pale stool, or abdominal symptoms can signal liver injury and require prompt action. People with cirrhosis were not studied in the phase 3 trials.

Fezolinetant is not an antidepressant and is not intended to treat depression, anxiety, or vaginal symptoms. Drug interactions and liver history can make another option more appropriate.

Elinzanetant

Elinzanetant is a dual neurokinin-1 and neurokinin-3 receptor antagonist. In the OASIS 1 and OASIS 2 randomized phase 3 trials, it reduced vasomotor-symptom frequency and severity more than placebo at weeks 4 and 12 and improved measures of sleep disturbance and menopause-related quality of life [5]. The FDA approved Lynkuet in October 2025 for moderate-to-severe vasomotor symptoms due to menopause [6].

The approved product is taken at bedtime, and somnolence, fatigue, or dizziness can matter for driving, falls, and other sedating medicines. Liver disease, kidney disease, and interacting medicines need label-based review. The fact that elinzanetant is nonhormonal does not mean it is interaction-free or appropriate for every patient.

SSRIs and SNRIs

Low-dose paroxetine is FDA-approved for moderate-to-severe vasomotor symptoms. Other agents, including venlafaxine, desvenlafaxine, escitalopram, and citalopram, are used off label and supported by varying trial evidence [1]. In a randomized trial among breast-cancer survivors, venlafaxine reduced hot-flash scores compared with placebo [7].

Choice can be guided by depression or anxiety, sexual adverse effects, blood pressure, withdrawal sensitivity, other medicines, and prior response. These drugs should not be swapped or stopped abruptly without a plan because discontinuation symptoms can occur.

Paroxetine and fluoxetine strongly inhibit CYP2D6, an enzyme involved in converting tamoxifen to active metabolites. A pharmacogenetic study demonstrated that CYP2D6 genotype and inhibitor use changed endoxifen concentrations [10]. People taking tamoxifen should have the antidepressant choice coordinated with oncology and use a suitable alternative when possible.

Gabapentin

Gabapentin can reduce vasomotor symptoms and may be useful when nighttime symptoms dominate. A randomized trial found benefit at a total daily dose of 900 mg compared with placebo [8]. Dizziness, sedation, gait instability, and dose adjustment for kidney function are important, particularly in older adults or when combined with alcohol, opioids, sleep medicines, or other sedatives.

Oxybutynin

Oxybutynin reduced hot-flash frequency and severity in a randomized trial that included women with and without breast cancer [9]. Dry mouth, constipation, blurred vision, urinary retention, and anticholinergic cognitive effects can limit use. It may be a poor fit for a person with glaucoma, retention risk, constipation, cognitive vulnerability, or a high cumulative anticholinergic burden.

Clonidine, supplements, and compounded products

Clonidine is no longer a preferred vasomotor treatment because benefit is limited and adverse effects can include dizziness and blood-pressure problems [1]. The 2023 evidence review did not recommend herbal remedies, dietary supplements, soy extracts, cannabinoids, acupuncture, cooling techniques, or trigger avoidance as treatments for vasomotor symptoms because consistent clinically meaningful efficacy was not established [1].

That does not mean a fan, layered clothing, or avoiding a personal trigger cannot make an episode easier to tolerate. It means these strategies should not be presented as substitutes for proven treatment when symptoms interfere with daily life. “Bioidentical” compounded mixtures are not nonhormonal merely because they are marketed as natural; they may contain estrogens, progesterone, testosterone, or other active hormones.

Cognitive behavioral therapy and sleep

Menopause-focused cognitive behavioral therapy can reduce how distressing and intrusive hot flashes feel. In MENOS 2, group and self-help CBT improved problematic hot-flash and night-sweat ratings compared with usual care [11]. CBT does not need to eliminate every physiologic hot flash to improve sleep, coping, and quality of life.

Insomnia deserves its own diagnosis. Repeated awakenings can come from vasomotor symptoms, sleep apnea, restless legs, pain, alcohol, urinary symptoms, depression, anxiety, or circadian changes. CBT for insomnia, an apnea assessment when indicated, and treatment of nocturia or pain can be more useful than escalating a hot-flash drug when sweats are not the main cause.

Exercise is important for cardiovascular health, strength, balance, sleep, and mood, but randomized evidence has not consistently shown that it treats vasomotor symptoms [1]. A recommendation to exercise should name the expected benefit rather than promise that hot flashes will disappear.

Genitourinary syndrome without systemic HRT

Genitourinary syndrome of menopause can include dryness, burning, irritation, pain with penetration, urinary urgency, and recurrent urinary infections. Unlike hot flashes, these symptoms often persist or progress without targeted care.

Nonhormonal starting options include:

• a lubricant used during sexual activity;
• a vaginal moisturizer used regularly rather than only during sex;
• pelvic-floor physical therapy when muscle overactivity, guarding, or pain contributes;
• evaluation for infection, dermatologic disease, pelvic-floor dysfunction, and other causes when symptoms do not fit simple dryness.

A 12-week randomized trial found that symptom improvement was substantial in all arms and did not show a significant advantage for a low-dose vaginal estradiol tablet or moisturizer over dual placebo gel/tablet for the most bothersome symptom [13]. This does not prove all treatments are equivalent in every patient; it shows a large placebo and gel effect and supports individualized trials rather than exaggerated promises.

Low-dose vaginal estrogen, vaginal prasterone, and oral ospemifene are different options when nonhormonal measures are inadequate. They are not systemic HRT, but neither are all of them hormone-free. A history of estrogen-sensitive cancer calls for shared decision-making with the treating oncology team, especially after nonhormonal options fail.

Persistent bleeding, a lesion, unexplained discharge, or focal pain needs examination. Recurrent “UTIs” should be confirmed when possible because bladder pain and GSM can mimic infection.

How fast HRT works if the decision changes

Systemic hormone therapy remains the most effective treatment for vasomotor symptoms [2]. Some people reconsider after nonhormonal treatment is ineffective or poorly tolerated. Improvement often begins within weeks, but the exact onset depends on symptom pattern, formulation, dose, adherence, and individual response. A rigid statement that every person must improve by a specific week is not evidence-based.

Before changing dose, confirm that the symptom being tracked is actually estrogen-responsive. Persistent insomnia, palpitations, pain, or depression may have another cause. People with a uterus need adequate endometrial protection when systemic estrogen is used. New bleeding after starting or changing therapy should be assessed according to timing and pattern.

Can HRT be stopped cold turkey?

Menopausal hormone therapy can generally be stopped abruptly, but vasomotor symptoms may recur. Randomized evidence has not shown a durable advantage for tapering. In one prospective randomized study, gradual discontinuation delayed symptom return early but did not prevent it, and outcomes were similar by later follow-up [12].

The practical choice can still be individualized. A taper may help someone judge the lowest dose that controls symptoms or feel more comfortable during a planned transition. Abrupt stopping may be simpler or medically necessary. There is no validated universal schedule that steps every patch or tablet down at fixed intervals.

Stopping systemic estrogen does not mean all care stops. A person can transition to a nonhormonal hot-flash medicine, continue treatment for genitourinary symptoms, and update bone or cardiovascular prevention separately.

How long can HRT continue?

There is no universal birthday or fixed number of years at which menopausal hormone therapy must stop. The 2022 Menopause Society position statement says the benefit-risk ratio is generally most favorable for symptomatic people younger than 60 or within 10 years of menopause onset who do not have contraindications [2]. Starting later carries greater absolute cardiovascular, stroke, clot, and dementia risks.

Longer use can be reasonable for persistent symptoms or osteoporosis prevention after periodic reevaluation. Long-term follow-up of the randomized Women's Health Initiative trials found no significant difference in all-cause mortality for hormone therapy compared with placebo, but that result does not erase formulation-specific or individual risks [14]. The review should cover the current indication, whether the dose and route remain appropriate, uterine protection, bleeding, breast and cardiovascular risk, and available alternatives. Continuing therapy is not the same as renewing it automatically without reassessment.

Hormone therapy should not be used to prevent coronary disease or dementia. Estrogen-only therapy after hysterectomy and combined estrogen-progestogen therapy have different breast and endometrial considerations. Route and progestogen choice may also matter, but observational differences should not be presented as guarantees.

HRT, perimenopause, and pregnancy

Menopausal hormone therapy is not contraception. During perimenopause, ovulation can still occur even when periods are irregular or months apart. A person who could become pregnant needs a separate contraceptive plan until menopause is established or contraception is no longer required based on age and clinical guidance.

A levonorgestrel intrauterine system may provide contraception and, depending on product age and local guidance, endometrial protection alongside estrogen. Combined hormonal contraception can control bleeding and some menopausal symptoms for selected medically eligible users, but it is not the same as standard HRT and usually carries different estrogen exposure and eligibility rules.

If pregnancy occurs, menopausal hormone therapy should be reviewed promptly. HRT is not a fertility treatment and does not protect against pregnancy complications.

Bone and cardiovascular health without HRT

Avoiding HRT does not leave bones or the heart untreated. Bone care includes resistance and weight-bearing activity, balance and fall prevention, adequate dietary protein and calcium, correction of vitamin D deficiency when present, smoking cessation, and limiting excess alcohol.

Bone-density screening is risk based. U.S. preventive guidance recommends screening women at age 65 and younger postmenopausal women whose fracture risk is high enough to warrant testing, rather than automatically scanning everyone at menopause onset [15]. A fragility fracture, long-term glucocorticoid use, low body weight, early menopause, or another major risk can justify earlier assessment.

Cardiovascular prevention uses standard risk assessment: blood pressure, lipids, diabetes, smoking, family history, activity, and weight trajectory. Menopausal hormone therapy is not prescribed for primary cardiovascular prevention. Conversely, being postmenopausal does not automatically mean a statin, aspirin, or supplement is needed.

A practical nonhormonal treatment pathway

1. Name the dominant symptom. Separate vasomotor symptoms from insomnia, depression, GSM, migraine, or musculoskeletal pain.

2. Clarify why systemic hormones are being avoided. Preference, prior adverse effects, breast-cancer therapy, blood-clot history, liver disease, or unexplained bleeding lead to different choices.

3. Match the option to comorbidities and medicines. Review liver function for fezolinetant, sedation and interactions for elinzanetant or gabapentin, CYP2D6 inhibition with tamoxifen, blood pressure with SNRIs, and anticholinergic burden with oxybutynin.

4. Define one measurable outcome. Use hot flashes per day, nighttime awakenings, a validated bother score, pain with sex, or a daily-life goal.

5. Reassess efficacy and tolerability. A drug can be biologically active yet not provide enough benefit for the individual. Side effects, adherence, and competing diagnoses matter.

6. Treat long-term health separately. Bone, cardiovascular, sexual, urinary, mood, and sleep care should continue whether systemic hormones are used or not.